全部分类
  • WAY-204688 (SIM-688)
WAY-204688 (SIM-688)的可视化放大

WAY-204688 (SIM-688)

WAY-204688 (SIM-688) 是一种雌激素受体 (ER-α) 选择性、口服活性的 NF-κB 转录活性抑制剂,IC50 为 122±30 nM 作用于 NF-κB-荧光素酶κB-luc) 在 HAECT-1 细胞中。

此产品仅用于科学研究,我们不为任何个人用途提供产品和服务

WAY-204688 (SIM-688)的二维码
  • 库存: 现货
可选规格
  • 包装
    价格
    促销价
    数量
  • 1mg
    ¥5387.00
    4310.00
    - +
  • 5mg
    ¥10687.00
    8550.00
    - +
  • 10mg
    ¥16875.00
    13500.00
    - +
  • 20mg
    ¥31725.00
    25380.00
    - +
已选 0 0
金额: ¥0.00
首页 收藏
  • 货号: ajce47838
  • CAS: 796854-35-8
  • 别名: SIM-688
  • 分子式: C34H31F3N2O2
  • 分子量: 556.62
  • 纯度: >98%
  • 溶解度: Soluble in DMSO
  • 储存: Store at -20°C
  • 库存: 现货

Background

WAY-204688 is an estrogen receptor (ER-α) selective, orally active inhibitor of NF-κB transcriptional activity with an IC50 of 122 ± 30 nM for NF-κB-luciferase (NF-κB-luc) in HAECT-1 cells.


WAY-204688 is ER-dependenrt (activity seen only when hER is coexpressed with NF-κB-luciferase in human aortic endothelial cell lines (HAECT-1) cells). The interaction of WAY-204688 with ERα and ERβ is examined in vitro. WAY-204688 displaces [3H]E2 from the ERα ligand binding domain protein (LBD) with IC50=2.43 μM and from the ERβ ligand binding domain protein (LBD) with IC50=1.5 μM[1].


WAY-204688 (5 mg/kg per day, po daily for 5 weeks) is evaluated in vivo for the ability to inhibit four proinflammatory genes (MHC, invariant chain (MHI), VCAM-1, RANTES, and TNF-α). The effect of WAY-204688 on induction of the gene products and on uterine wet weight is compared to that of 17α-ethinyl 17β-estradiol (EE at 10 μg/kg per day) in the same paradigm. Further characterization of WAY-204688 is carried out in several preclinical models of inflammatory disease. In the Lewis rat adjuvant-induced arthritis model (AIA), WAY-204688 is active at a dose of 0.3 mg/kg per day, po[1].


[1]. Caggiano TJ, et al. Estrogen receptor dependent inhibitors of NF-kappaB transcriptional activation-1 synthesis and biological evaluation of substituted 2-cyanopropanoic acid derivatives: pathway selective inhibitors of NF-kappaB, a potential treatment for rheumatoid arthritis. J Med Chem. 2007 Nov 1;50(22):5245-8.

温馨提示 ×
商品已成功加入购物车!
购物车共 0 件商品
去购物车结算